AgingResearch.News
Diabetes, Obesity & Metabolism

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network

By Léna Robert, Inès Belalem, Corinne Vigouroux, Show 9 more authorsSophie Lamothe
Figure 1. Study flow diagram. Short term = 12 ± 6 months of SGLT2i therapy.
Open the figure at full size
Figure 1. Study flow diagram. Short term = 12 ± 6 months of SGLT2i therapy.Study flow diagram. Short term = 12 ± 6 months of SGLT2i therapy.Robert et al.
Cohort study in peopleInterventions

Declared ties to: Amryt Pharmaceuticals, Sanofi, Ipsen and 8 more

Paper

The paper

Léna Robert, Inès Belalem, Corinne Vigouroux, Show 9 more authorsSophie Lamothe

Assistance Publique – Hôpitaux de Paris

Diabetes, Obesity & Metabolism, 19 Aug 2026

doi.org/10.1111/dom.71126PubMed 42618535

More on SGLT2 inhibitors